HUTCHMED will present a Research & Development update on October 31, 2025, in Shanghai and via webcast.
Quiver AI Summary
HUTCHMED (China) Limited announced a Research & Development update event scheduled for October 31, 2025, in Shanghai and via webcast. Dr. Michael Shi, the company's Executive Vice President and Chief Medical Officer, will present the company’s R&D strategy, highlighting their Antibody Targeted Therapy Conjugates platform and updates on their late-stage pipeline. The in-person event will run from 3:00 p.m. to 5:00 p.m. HKT in Chinese, with a separate English webcast at 8:00 p.m. HKT. Attendance to the Shanghai event is by invitation only, but both webcasts will be available live on the company website. HUTCHMED focuses on developing targeted therapies and immunotherapies for cancer and immunological diseases, with products marketed in China and approved in other countries, including the US.
Potential Positives
- HUTCHMED is hosting a Research & Development update, showcasing a commitment to transparency and engagement with stakeholders regarding its R&D strategy and vision.
- The event will highlight the Antibody Targeted Therapy Conjugates platform and its lead candidate HMPL-A251, potentially attracting investor interest and building confidence in the company's pipeline.
- Additionally, the availability of a live webcast and replay ensures broader accessibility for global stakeholders and investors, facilitating greater outreach.
Potential Negatives
- Attendance at the in-person event is by invitation only, which may limit transparency and stakeholder engagement.
- The emphasis on forward-looking statements highlights potential risks and uncertainties regarding the company's future performance and developments.
- The lack of specifics regarding the progress of the late-stage pipeline may raise concerns among investors about the company's current standing and potential commercial success.
FAQ
When will HUTCHMED host its R&D update event?
HUTCHMED will host its R&D update on Friday, October 31, 2025.
How can I attend the HUTCHMED R&D update?
The in-person event is by invitation only, but a live webcast will be available.
What topics will be discussed during the R&D update?
Dr. Michael Shi will share insights into HUTCHMED’s R&D strategy, including Antibody Targeted Therapy Conjugates.
What time is the webcast for the R&D update?
The English webcast will start at 8:00 p.m. HKT / 8:00 a.m. EDT on October 31, 2025.
Where can I find more information about the R&D update?
More information and the webcasts will be available on HUTCHMED’s official website at www.hutch-med.com/event/.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$HCM Hedge Fund Activity
We have seen 26 institutional investors add shares of $HCM stock to their portfolio, and 36 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SCHRODER INVESTMENT MANAGEMENT GROUP removed 264,164 shares (-9.3%) from their portfolio in Q2 2025, for an estimated $3,975,668
- GOLDMAN SACHS GROUP INC added 195,216 shares (+207.9%) to their portfolio in Q2 2025, for an estimated $2,938,000
- UBS GROUP AG removed 152,179 shares (-70.3%) from their portfolio in Q2 2025, for an estimated $2,290,293
- XY CAPITAL LTD removed 99,645 shares (-88.1%) from their portfolio in Q2 2025, for an estimated $1,499,657
- ALLIANZ ASSET MANAGEMENT GMBH removed 80,000 shares (-8.0%) from their portfolio in Q2 2025, for an estimated $1,204,000
- BLACKROCK, INC. removed 54,341 shares (-74.1%) from their portfolio in Q2 2025, for an estimated $817,832
- HENNION & WALSH ASSET MANAGEMENT, INC. removed 48,769 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $733,973
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$HCM Analyst Ratings
Wall Street analysts have issued reports on $HCM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 07/22/2025
To track analyst ratings and price targets for $HCM, check out Quiver Quantitative's $HCM forecast page.
Full Release
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a Research & Development update in Shanghai, China, and via webcast on Friday, October 31, 2025.
During the event, Dr. Michael Shi, Executive Vice President, Head of R&D and Chief Medical Officer of HUTCHMED, will share insights into the Company’s R&D strategy and vision. This will include an overview of the Company’s Antibody Targeted Therapy Conjugates platform, featuring its lead candidate HMPL-A251, as well as updates on late-stage pipeline development.
The in-person event will be held in Shanghai from 3:00 p.m. to 5:00 p.m. HKT and conducted in Chinese (Putonghua). A live webcast will be available concurrently. Attendance at the in-person event is by invitation only.
A webcast in English will be held from 8:00 p.m. HKT / 8:00 a.m. EDT / 12:00 noon GMT on Friday, October 31, for approximately one hour.
Both webcasts will be available live via the company website at www.hutch-med.com/event/ . A replay will also be available on the website shortly after the event.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the U.S. Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
CONTACTS
| Investor Enquiries | +852 2121 8200 / [email protected] |
| Media Enquiries | |
| FTI Consulting – | +44 20 3727 1030 / [email protected] |
| Ben Atwell / Alex Shaw | +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / [email protected] |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| Deutsche Numis | Joint Broker |
| Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |
